Benzinga's Microcap Movers for Monday March 5, 2012

Below are highlights from Benzinga's daily coverage of microcap securities making big moves: TranS1 Shares of TranS1 TSON, the Wilmington, NC medical device company, rose 24% Monday on 17 times the average daily volume. TranS1 announced Monday that the American Medical Association Current Procedural Terminology Panel has voted to approve an application for a Category I CPT code for L5-S1 spinal fusion utilizing TranS1's pre-sacral interbody fusion approach with its AxiaLIF implant. This coding change was recently disclosed on the AMA website and will become effective on January 1, 2013. The Company will provide further information during its fourth quarter 2011 results conference call on March 8, 2012. TSON closed at $4.07 on Monday. BioLineRx Shares of BioLineRx GRVY, the Jerusalem-based clinical-stage biopharmaceutical development company, rose 2.28% Monday on half the average daily volume. BioLineRx announced Monday that it has received approval from the Israeli Ministry of Health for commencing a Phase II clinical trial of BL-7040, an orally available molecule for treating Inflammatory Bowel Disease. This Phase II trial will be an open-label study to evaluate the efficacy, pharmacodynamics, safety and tolerability of oral BL-7040 in up to 20 patients with moderately active ulcerative colitis, a type of IBD. Patients will be treated for up to five weeks with BL-7040: 12mg/day for up to three weeks followed by 40mg/day for two additional weeks. The clinical trial will be carried out at two sites in Israel: Sourasky Medical Center in Tel Aviv and Hadassah Medical Center in Jerusalem. BioLineRx closed at $3.14 on Monday. Sunesis Pharmaceuticals Shares of Sunesis Pharmaceuticals SNSS, the San Francisco, CA biopharmaceutical company, rose 18% Monday on 3.5 times the average daily volume. Sunesis will be presenting at the Cowen and Company 32nd Annual Health Care Conference on Tuesday, March 6, 2012 at 8:40 AM Eastern Time at the Boston Marriott Copley Place in Boston, MA. Sunesis Pharmaceuticals closed at $2.04 on Monday.